Imputation methods for missing outcome data in meta-analysis of clinical trials

Clinical Trials

Volumn 5, Issue 3, 2008, Pages 225-239

  Higgins, Julian P T ^a   White, Ian R ^a   Wood, Angela M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; PLACEBO;

ARTICLE; CLINICAL TRIAL; DATA ANALYSIS; DATA COLLECTION METHOD; DATA EXTRACTION; HUMAN; INFORMATION PROCESSING; INFORMATION RETRIEVAL; MATHEMATICAL COMPUTING; META ANALYSIS; METHODOLOGY; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT OUTCOME; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; STATISTICS; UNCERTAINTY;

HALOPERIDOL; HUMANS; META-ANALYSIS AS TOPIC; MODELS, STATISTICAL; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SCHIZOPHRENIA; UNCERTAINTY;

EID: 54549102237     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774508091600     Document Type: Article

References (45)

1. Jüni P., Altman DG, Egger M. Assessing the quality of controlled clinical trials. BMJ 2001; 323: 42-46.
2. Hollis S., Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999; 319: 670-74.
3. Little Rja, Rubin DB Statistical Analysis with Missing Data. Hoboken, New Jersey, Wiley, 2002.
4. Wood AM, White IR, Thompson SG Are missing outcome data adequately handled? A review of published randomized controlled trials in major medical journals. Clin Trials 2004; 1: 368-76.
5. Whitehead A., Whitehead J. A general parametric approach to the meta-analysis of randomised clinical trials. Stat Med 1991; 10: 1665-77.
6. Henderson R., Diggle P., Dobson A. Joint modeling longitudinal measures and event time data. Biostatistics 2000; 4: 465-80.
7. Kenward MG, Goetghebeur EJ, Molenberghs G. Sensitivity analysis for incomplete categorical data. Statistical Modelling 2001; 1: 31-48.
8. Rubin DB Formalizing subjective notions about the effect of nonrespondents in sample surveys. J Am Statist Assoc 1977; 72: 538-43.
9. Forster JJ, Smith PWF. Model-based inference for categorical survey data subject to non-ignorable nonresponse. J R Statist Soc B 1998; 60: 57-70.
10. Thompson SG, Higgins JPT. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21: 1559-74.
11. Higgins JPT, Thompson SG Controlling the risk of spurious findings from meta-regression. Stat Med 2004; 23: 1663-82.
12. Rubin DB Multiple Imputation for Non Response in Surveys. New York, NY, Wiley, 1987.
13. Miller ME, Morgan TM, Espeland MA, Emerson SS Group comparisons involving missing data in clinical trials: A comparison of estimates and power (size) for some simple approaches. Stat Med 2001; 20: 2383-97.
14. Gould AL A new approach to the analysis of clinical drug trials with withdrawals. Biometrics 1980; 36: 721-27.
15. Tashkin DP, Kanner R., Bailey W., et al. Smoking cessation in patients with chronic obstructive pulmonary disease: A double-blind, placebo-controlled, randomised trial. Lancet 2001; 357: 1571-75.
16. Hajek P., Stead LF Aversive smoking for smoking cessation. Cochrane Database Syst Rev 2001; 3: CD000546.
17. Gamble C., Hollis S. Uncertainty method improved on best-worst case analysis in a binary meta-analysis. J Clin Epidemiol 2005; 58: 579-88.
18. Magder LS Simple approaches to assess the possible impact of missing outcome information on estimates of risk ratios, odds ratios, and risk differences. Controlled Clin Trials 2003; 24: 411-21.
19. Rotnitzky A., Robins JM, Scharfstein DO Semiparametric regression for repeated outcomes with nonignorable nonresponse. J Am Statist Assoc 1998; 93: 1321-39.
20. Little RJA. Pattern-mixture models for multivariate incomplete data. J Am Statist Assoc 1993; 88: 125-34.
21. Nordheim EV Inference from nonrandomly missing categorical data: An example from a genetic study on Turner's syndrome. J Am Statist Assoc 1984; 79: 772-80.
22. Kadane JB Subjective Bayesian analysis for surveys with missing data. Statistician 1993; 42: 415-26.
23. Scharfstein DO, Daniels MJ, Robins JM Incorporating prior beliefs about selection bias into the analysis of randomized trials with missing outcomes. Biostatistics 2003; 4: 495-512.
24. White IR, Higgins JPT, Wood AM Allowing for uncertainty due to missing data in meta-analysis, Part 1: Two-stage methods. Stat Med 2008; 27: 711-727.
25. Joy CB, Adams CE, Lawrie SM Haloperidol versus placebo for schizophrenia. Cochrane Database Syst Rev 2006; 4: CD003082.
26. Vichaiya V. Clinical trial of haloperidol in schizophrenia. Journal of the Psychiatric Association of Thailand 1971; 16: 31-42.
27. Bechelli LP, Ruffino-Netto A., Hetem G. A double-blind controlled trial of pipotiazine, haloperidol and placebo in recently-hospitalized acute schizophrenic patients. Braz J Med Biol Res 1983; 16: 305-11.
28. Durost H., Lee H., Arthurs D. An early evaluation of haloperidol. In: Lehmann HE, Ban TA. (eds). The Butyrophenones in Psychiatry Quebec Psychopharmacological Research Association, 1964, pp. 70-71.
29. DerSimonian R., Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986; 7: 177-88.
30. Arvanitis LA, Miller BG Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997; 42: 233-46.
31. Beasley C-MJ, Tollefson G., Tran P., et al. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14: 111-23.
32. Borison RL, Pathiraja AP, Diamond BI, Meibach RC Risperidone: Clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992; 28: 213-18.
33. Chouinard G., Jones B., Remington G., et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13: 25-40.
34. Garry JW, Leonard TJ Haloperidol: A controlled trial in chronic schizophrenia. Br J Psychiatry 1962; 108: 105-07.
35. Howard JS Haloperidol for chronically hospitalized psychotics: A double-blind comparison with thiothixine and placebo; a follow-up open evaluation. Dis Nerv Syst 1974; 35: 458-63.
36. Marder SR, Meibach RC Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825-35.
37. Nishikawa T., Tsuda A., Tanaka M., et al. Prophylactic effect of neuroleptics in symptom-free schizophrenics. Psychopharmacology 1982; 77: 301-04.
38. Nishikawa T., Tsuda A., Tanaka M., et al. Prophylactic effect of neuroleptics in symptom-free schizophrenics: A comparative dose-response study of haloperidol and propericiazine. Psychopharmacology 1984; 82: 153-56.
39. Reschke RW Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia. Dis Nerv Syst 1974; 35: 112-15.
40. Selman FB, McClure RF, Helwig H. Loxapine succinate: A double-blind comparison with haloperidol and placebo in acute schizophrenics. Curr Ther Res Clin Exp 1976; 19: 645-52.
41. Serafetinides EA, Collins S., Clark ML Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. J Nerv Ment Dis 1972; 154: 31-42.
42. Simpson GM, Angus JW, Edwards JG A controlled study of haloperidol in chronic schizophrenia. Curr Ther Res Clin Exp 1967; 9: 407-12.
43. Spencer EK, Kafantaris V., Padron-Gayol MV, et al. Haloperidol in schizophrenic children: Early findings from a study in progress. Psychopharmacol Bull 1992; 28: 183-86.
44. Hollis S. A graphical sensitivity analysis for clinical trials with non-ignorable missing binary outcome. Stat Med 2002; 21: 3823-34.
45. Higgins JPT, Thompson SG, Deeks JJ, Altman DG Measuring inconsistency in meta-analysis. BMJ 2003; 327: 557-60.